Segall Bryant & Hamill’s BioMarin Pharmaceuticals BMRN Stock Holding History

Segall Bryant & Hamill’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,447	Closed	-$256K	–	550
2015 Q4	$256K	Sell	2,447 -87	-3%	-$9.09K	0.01%	486
2015 Q3	$267K	Sell	2,534 -705	-22%	-$94.2K	0.01%	490
2015 Q2	$443K	Buy	3,239 +754	+30%	+$93.4K	0.01%	438
2015 Q1	$310K	Buy	+2,485	New	+$263K	0.01%	481

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Segall Bryant & Hamill's BMRN Position: Q1 2016 in Review

Segall Bryant & Hamill sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 2,447 shares — an estimated $256K sold.

Segall Bryant & Hamill first reported a position in BMRN in Q1 2015 and held it in 4 quarters. The position peaked at $443K in Q2 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Segall Bryant & Hamill reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Segall Bryant & Hamill sold 2,447 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $256K.
Segall Bryant & Hamill first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 4 quarters.
Segall Bryant & Hamill's BioMarin Pharmaceuticals position peaked at $443K in Q2 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Segall Bryant & Hamill's 13F filing for Q1 2016, filed 12 May 2016.